McKesson: Solid Q1 Earnings And Management Execution (Rating Upgrade)

McKesson posted strong Q1 results with EPS up 20% and revenue up 7.7%, and it modestly raised FY27 EPS guidance. Despite the beat, the outlook is tempered by expectations that GLP-1-driven momentum will decelerate and top-line growth may soften. The Wellverse spin-off (plus prior divestitures) is streamlining MCK, which could support a premium multiple versus peers.

Analysis

The near-term read-through is that MCK is transitioning from a growth-by-coincidence story to a cleaner operating story: less dependence on one hot category, more emphasis on execution and capital allocation. That is usually supportive of a higher multiple only if the market believes the earnings base is becoming more durable; otherwise, slowing top-line momentum can cap rerating even when EPS trends better than revenue. In the distribution group, that makes MCK less of a momentum name and more of a quality compounder relative to Cencora (COR) and Cardinal Health (CAH).

The second-order issue is mix. If GLP-1 volumes cool, the market may underappreciate the impact on working capital intensity and gross profit dollars even if reported revenue still looks solid; lower growth can actually improve free cash flow conversion, but it also removes a visible narrative that supported valuation premium. Over 1-3 months, the key catalyst is whether management can keep FY27 guide upward with stable core distribution margins rather than relying on category-specific volume tailwinds.

Contrarian view: the consensus may be overfocusing on the spin-off/divestiture optics and underestimating how much of the premium case depends on continued simplification without sacrificing scale economics. If the market starts treating MCK as a slower-growth, lower-volatility utility-like distributor, the stock could deserve a steadier multiple but not necessarily a materially higher one. What would falsify the bullish thesis is any sign that GLP-1 deceleration spills into core prescription volume, or that the next guidance reset shows margin gains are coming at the expense of organic growth.

Key Decisions for Investors

• Stay constructive on MCK, but favor a staggered entry on weakness rather than chasing the move; the cleanest long case is 6-18 months out if spin-off simplification converts into sustained FCF and peer-leading ROIC.
• Relative-value trade: long MCK / short CAH or COR if the market begins paying up for quality and balance-sheet simplification; exit if MCK fails to hold a premium multiple after the next earnings print.
• Use a call spread instead of outright stock if you want exposure to a rerating catalyst: upside is tied to multiple expansion from cleaner reporting, while downside is limited if growth decelerates faster than expected over the next 1-3 months.
• Watch GLP-1 contribution and organic revenue ex-divestitures as the key falsifiers; if either slows materially, reduce exposure because the bull case shifts from 'growth plus simplification' to 'simplification only.'
• If MCK trades at a sustained premium to peers without an improving organic growth runway, fade the multiple expansion with a tactical short against COR as the more diversified distribution comp.